Liver fibrosis and type 2 diabetes modulate postprandial incretin and glucagon responses in fatty liver disease

Le résumé fourni par la source

The study aims to characterize the secretion dynamics of glucagon-related peptides, including GLP-1, GIP, and GLP-2, across different stages of metabolic-associated steatotic liver disease (MASLD), while evaluating the impact of type 2 diabetes (T2D) on these hormonal responses. Thirty-four MASLD subjects were stratified according with the liver transient elastography (TE ≥ 9 kPa) and T2D in NF (no fibrosis, without T2D; n = 12), NFD (no fibrosis, with T2D; n = 8), F (fibrosis, without T2D; n = 5), and FD (fibrosis, with T2D; n = 9) and completed a standardized 3-h meal tolerance test (MTT). The presence of liver fibrosis, regardless of diabetes status, was associated with hyperglycemia, hyperinsulinemia, and greater insulin resistance compared to the non-fibrosis (NF) group. Significant differences in glucagon and GLP-1 response curves were observed across groups. People with T2D showed an elevated peak of glucagon and increased glucagon exposure, as indicated by both the 60-min area under the curve (AUC60') and total AUC during the MTT. In the FD group, fasting and peak GLP-1 levels, as well as AUC60' and total AUC GLP-1, were 1.9-, 1.8-, and 1.9-fold higher, respectively, compared to the NF group. GIP responses were similar across groups, except for elevated fasting levels in NFD (p = 0.002). GLP-2 mirrored GLP-1, with FD showing the highest fasting and postprandial levels. Stepwise regression identified fibrosis and FPG as the main predictors of GLP-1, while glucagon was linked to FPG, HbA1c, and BMI. Liver fibrosis and T2D impact glucagon-related peptides responses in MASLD, revealing important metabolic alterations that may guide therapeutic approaches.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.